HPV InfectionPhase 2NCT06756269
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
A Phase 2 study testing Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine and 9-HPV vaccine in people with HPV Infection and HPV-Related Carcinoma, run by Shanghai Bovax Biotechnology Co., Ltd. at 1 site in China.
Trial summary
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants. Read more about this study
- Who is it for?
- Ages 9 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia
- What is being tested?
- Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine and 9-HPV vaccine
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 330 participants
- Where
- 1 siteChina
- Study dates
- 15 Jan 2025to 13 Jan 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 to 45 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Participants aged 9-45；
- Participants aged 18-45 who can provide legal identification，participants aged 9-17 and their guardian can provide legal identification；
- Participants and/or their guardian sign an informed consent form;
- Axillary temperature less than 37.3 ℃（>14 years old）or less than 37.5℃（≤14 years old）at the time of enrollment；
- Be able to comply with study protocol requirements；
- Women with reproductive age take effective contraceptive measures within 2 weeks before enrollment in the study, and were not pregnant at the time of enrollment (negative blood pregnancy test), did not have lactation period, and had no birth plan within the 30 days after receiving the whole vaccination;
- Agree to take effective contraceptive measures within 30 days after receiving the whole vaccination (effective contraceptives include: oral contraceptives, injection or embedding contraceptives, sustained release topical contraceptives, hormone patches, intrauterine devices), sterilization, abstinence, condoms (male), diaphragms, cervical caps, etc.
Who cannot join
- Have been vaccinated with other HPV vaccines or planned to vaccinate other HPV vaccines during the study period；
- Plan to participate other clinical trials during the study period，or participated other clinical trials （including vaccine or drug）and received medication or vaccine within 3 months before enrollment ,
- History of positive HPV testing (including types not covered by the trial vaccine) among the participants aged 18-45 years old;
- History of CIN2/AIS/Cervical Cancer/Pelvic radiation therapy in female participants;
- History of HPV-related external genital diseases (such as genital warts, Vulvar intraepithelial neoplasia, Vaginal intraepithelial neoplasia, Penis/perianal/perineum intraepithelial neoplasia, Penile/perianal/perineal cancer) 、anal intraepithelial neoplasia and related cancer, or head and neck cancer；history of sexually transmitted diseases (including syphilis， Gonorrhea, genital chlamydia infection, genital herpes, soft chancre, sexually transmitted lymphogranuloma, inguinal granuloma, etc.);
- Has been diagnosed as having congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection/AIDS, SCID; Or Autoimmune Diseases (such as systemic lupus erythematosu, Rheumatoid arthritis, juvenile Rheumatoid arthritis, Pernicious Anemia, Ulcerative colitis, Type 1 diabetes, Graves' disease, hashimoto thyroiditi, etc.);
Show all 19Show fewer
- History of convulsions, epilepsy, except of febrile convulsions in children 5 years of age and younger;
- History of severe allergy that requires medical intervention, including but not limited to severe adverse reactions caused by vaccine or drug, eg anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenia sexual purpura, local allergic necrosis (Arthus reaction), widespread urticaria, dyspnea, angioedema, etc.; History of severe side effect caused by vaccination or severe allergy to any of the components of the investigational vaccine, including histidine, sodium chloride, aluminium phosphate, Polysorbate 80 and water for injection;
- Severe diseases, as determined by the investigator, that affect vaccination eligibility, whether past or current, include severe cardiovascular disease, severe liver and kidney disease, malignant tumor, and serious infectious disease, such as: tuberculosis, viral hepatitis, etc.;
- Before the enrollment, the physical examination was untreatment or uncontrolled hypertension, (18-45 year old: systolic blood pressure ≥140mmHg and / or diastolic blood pressure ≥90mmHg, 9-17 year old: systolic blood pressure ≥120mmHg and / or diastolic blood pressure ≥80mmHg);
- Coagulation disorders: such as Congenital or acquired hemophilia, Coagulation factor deficiency, clotting disorders, thrombocytopenia, etc.;
- No spleen or functional spleen, and no spleen caused by any condition;
- Receive any Immunosuppressive therapy product within 1 month prior to the first vaccination, or plan to receive such product from Day 0 to Month 7 (30 days after receiving the third dose of vaccination)，e.g. systemic medication for glucocorticoid (>20mg/day or 2mg/kg/day, continuous use ≥2 weeks), but local medication can be used (such as ointment, eye drops, inhalants) Or nasal spray);
- Receive any immunoglobulin or blood product within 3 months prior to the first injection, or plan to receive such product from Day 0 to Month 7 (30 days after receiving the third dose of vaccination);
- 3 days before vaccination, suffering from acute illness or acute exacerbation of chronic disease; using fever reducer, Antihistamines, and Analgesics(such as: Acetaminophen, Ibuprofen, loratadine, Cetirizine, etc. )
- Receiving inactivated vaccine or recombinant vaccine or live-attenuated vaccine or nucleic acid vaccine or adenovirus vaccine within 14 days before vaccination;
- History of mental disorders or family history of mental health disorder (immediate family);
- Plan to move out of the city before the end of the study or leave the local area for a long time during the scheduled study visit;
- The investigator believes that the participant has any condition that may interfere with the assessment of the purpose of the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
Nanning, Guangxi, 530028
Dabin Liang, 15977783657, gxirb2018@163.com
About this study
Official title: A Randomised, Double-blind, Placebo and Positive Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 9-45 Years
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
Read the detailed description
A Randomized, double-blind, placebo and positive controlled trial is planned in 330 healthy participants across two age groups (18-45 years and 9-17 years) to evaluate the safety and immunogenicity of the 15-valent HPV vaccine.
- Being tested
- Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, Placebo, 9-HPV vaccine
- Medical subject headings
- Papillomavirus Infections, Condylomata Acuminata
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Medium dose for 15-HPV vaccineBiological
Participants aged 9-45 years were given 3 doses of medium dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
High dose for 15-HPV vaccineBiological
Participants aged 9-45 years were given 3 doses of high dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
PlaceboBiological
Participants aged 9-45 years were given 3 doses of placebo intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
9-HPV vaccineBiological
Participants aged 9-45 years were given 3 doses of 9-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
| Study group | Role | What they receive |
|---|---|---|
| Medium dose for 15-HPV vaccine | Experimental | Participants aged 9-45 years were given 3 doses of medium dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule Receives: Biological: Medium dose for 15-HPV vaccine |
| High dose for 15-HPV vaccine | Experimental | Participants aged 9-45 years were given 3 doses of high dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule Receives: Biological: High dose for 15-HPV vaccine |
| Placebo | Placebo comparator | Participants aged 9-45 years were given 3 doses of placebo intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule Receives: Biological: Placebo |
| 9-HPV-vaccine | Active comparator | Participants aged 18-45 years were given 3 doses of 9-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule Receives: Biological: 9-HPV vaccine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Adverse Events
AE of local and systemic reactions within 30 minutes after each dose
Measured: Up to 30 minutes after any vaccination
Percentage of Participants With Solicited Adverse Events
The percentage of participants with one or more solicited AEs was assessed.
Measured: Up to 14 days after any vaccination
Percentage of Participants With Unsolicited Adverse Events
Percentage of Participants With Unsolicited Adverse Events
Measured: Up to 30 days after any vaccination
Percentage of Participants With Serious Adverse Events
The percentage of participants with one or more SAEs was assessed
Measured: From Day 0 after the first dose of vaccination to 6 months after the thrid dose
Percentage of Female Participants With Pregnancy Events
The percentage of participants with Pregnancy Events was assessed
Measured: From Day 0 after the first dose of vaccination to 6 months after the thrid dose
Secondary outcomes (3)
Immunogenicity after receiving 3 doses of 15-HPV vaccine
Geometric mean titer (GMT) of anti-vaccine containing corresponding type of neutralizing antibody in subjects aged 18-45 years on the 31-day after the third dose of immunization
Measured: Up to 31 days after the third vaccination
Immunogenicity of 15-HPV vaccine
Seroconversion rate （SCR）of the anti-vaccine containing the corresponding type of neutralizing antibody on day 31 after total immunization in subjects aged 18-45 years
Measured: Up to 31 days after the third vaccination
Immunogenicity after receiving 3 doses of 15-HPV vaccine among the participants
Geometric Mean Fold Increase (GMI) and 4-fold increase rates of anti-vaccine corresponding types of neutralizing antibodies in baseline seropositive subjects aged 18-45 years at day 31 after immunization
Measured: Up to 31 days after the third vaccination
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jan 2025
- Study start15 Jan 2025
- Primary completion30 Oct 2025
- Study completion13 Jan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HPV InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 330 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Yi Mo, Master, Principal investigator, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06756269
- Sponsor's protocol ID
- 15-HPV-2001
- Status last verified
- Dec 2025
- First submitted
- 31 Dec 2024
- Last updated
- 17 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Double-blind, Placebo and Positive Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 9-45 Years
- ClinicalTrials.gov ID
- NCT06756269
- Acronym / sponsor ID
- 15-HPV-2001
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 330 participants (estimated)
- Lead sponsor
- Shanghai Bovax Biotechnology Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 15 Jan 2025 (actual)
- Primary completion
- 30 Oct 2025 (actual)
- Study completion
- 13 Jan 2026 (estimated)
- First posted
- 1 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
Detailed description
A Randomized, double-blind, placebo and positive controlled trial is planned in 330 healthy participants across two age groups (18-45 years and 9-17 years) to evaluate the safety and immunogenicity of the 15-valent HPV vaccine.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Medium dose for 15-HPV vaccine | Experimental | Biological: Medium dose for 15-HPV vaccineParticipants aged 9-45 years were given 3 doses of medium dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule |
| High dose for 15-HPV vaccine | Experimental | Biological: High dose for 15-HPV vaccineParticipants aged 9-45 years were given 3 doses of high dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule |
| Placebo | Placebo comparator | Biological: PlaceboParticipants aged 9-45 years were given 3 doses of placebo intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule |
| 9-HPV-vaccine | Active comparator | Biological: 9-HPV vaccineParticipants aged 18-45 years were given 3 doses of 9-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule |
Who may qualify
- Ages
- 9 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (7 listed)
- Participants aged 9-45；
- Participants aged 18-45 who can provide legal identification，participants aged 9-17 and their guardian can provide legal identification；
- Participants and/or their guardian sign an informed consent form;
- Axillary temperature less than 37.3 ℃（>14 years old）or less than 37.5℃（≤14 years old）at the time of enrollment；
- Be able to comply with study protocol requirements；
Key exclusion criteria (19 listed)
- Have been vaccinated with other HPV vaccines or planned to vaccinate other HPV vaccines during the study period；
- Plan to participate other clinical trials during the study period，or participated other clinical trials （including vaccine or drug）and received medication or vaccine within 3 months before enrollment ,
- History of positive HPV testing (including types not covered by the trial vaccine) among the participants aged 18-45 years old;
- History of CIN2/AIS/Cervical Cancer/Pelvic radiation therapy in female participants;
- History of HPV-related external genital diseases (such as genital warts, Vulvar intraepithelial neoplasia, Vaginal intraepithelial neoplasia, Penis/perianal/perineum intraepithelial neoplasia, Penile/perianal/perineal cancer) 、anal intraepithelial neoplasia and related cancer, or head and neck cancer；history of sexually transmitted diseases (including syphilis， Gonorrhea, genital chlamydia infection, genital herpes, soft chancre, sexually transmitted lymphogranuloma, inguinal granuloma, etc.);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Medium dose for 15-HPV vaccineParticipants aged 9-45 years were given 3 doses of medium dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule | Biological | Medium dose for 15-HPV vaccine |
| High dose for 15-HPV vaccineParticipants aged 9-45 years were given 3 doses of high dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule | Biological | High dose for 15-HPV vaccine |
| PlaceboParticipants aged 9-45 years were given 3 doses of placebo intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule | Biological | Placebo |
| 9-HPV vaccineParticipants aged 9-45 years were given 3 doses of 9-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule | Biological | 9-HPV-vaccine |
Primary outcome
Percentage of Participants With Adverse Events
Time frame: Up to 30 minutes after any vaccination
AE of local and systemic reactions within 30 minutes after each dose
Percentage of Participants With Solicited Adverse Events
Time frame: Up to 14 days after any vaccination
The percentage of participants with one or more solicited AEs was assessed.
Percentage of Participants With Unsolicited Adverse Events
Time frame: Up to 30 days after any vaccination
Percentage of Participants With Unsolicited Adverse Events
Percentage of Participants With Serious Adverse Events
Time frame: From Day 0 after the first dose of vaccination to 6 months after the thrid dose
The percentage of participants with one or more SAEs was assessed
Percentage of Female Participants With Pregnancy Events
Time frame: From Day 0 after the first dose of vaccination to 6 months after the thrid dose
The percentage of participants with Pregnancy Events was assessed
3 secondary outcomes
Immunogenicity after receiving 3 doses of 15-HPV vaccine
Time frame: Up to 31 days after the third vaccination
Immunogenicity of 15-HPV vaccine
Time frame: Up to 31 days after the third vaccination
Immunogenicity after receiving 3 doses of 15-HPV vaccine among the participants
Time frame: Up to 31 days after the third vaccination
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for HPV Infection
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Active, not recruitingPhase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Immunization, HPV Infection
Not yet recruitingPhase 2
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
RecruitingPhase 2
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
RecruitingPhase 2
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yi Mo, Master principal investigator
Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine and 9-HPV vaccine in people with HPV Infection and HPV-Related Carcinoma, run by Shanghai Bovax Biotechnology Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dabin Liang (+86 15977783657, gxirb2018@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Adverse Events (time frame: Up to 30 minutes after any vaccination). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2025.